Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 61-64 of 64
Live/Bile Duct
Telemedicine for FGFR focused diagnostics & novel cholangio therapies
Telemedicine for FGFR focused diagnostics & novel cholangio therapies Summary: Cholangiocarcinoma is a rare and aggressive liver cancer affecting the bile duct. Patients with cholangiocarcinoma can benefit from clinical and genetics expertise found at university-based cancer centers. However, most patients cannot travel long distances and pay expensive out-of-pocket costs for this expert level of care. […]
Sameek Roychowdhury, MD, PhD
The Ohio State University
Pediatric Brain Cancer
Multicenter efficacy study of BLZ-100 tumor paint in pediatric tumors of the central nervous system
Multicenter efficacy study of BLZ-100 tumor paint in pediatric tumors of the central nervous system Summary: Brain tumors are the leading cause of cancer death in children. Complete resection greatly increases the chance of survival but often results in decreased quality of life. This is the phase II clinical efficacy study of BLZ-100 (Tumor Paint) […]
Sarah Leary, MD, MS
Seattle Children's
Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing durable responses. For example, approximately up to 20% of patients with metastatic non-small cell lung cancer (NSCLC) have durable clinical responses. However, this is not without toxicities. Immune-related adverse […]
Ajay Sheshadri, MD, MSCI
MD Anderson Cancer Center
Pediatric Blood Cancer
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia Summary: While a first remission is possible for pediatrics patients with acute myeloid leukemia (AML), only 60% will remain in long-term remission despite intensive therapy and allogeneic stem cell transplant (stem cell transplant from a donor). […]
Steven Devine, MD
Be The Match Foundation
